Director John W. Kozarich filed a Form 144 notice of proposed sale with the SEC on November 12, 2026, disclosing plans to sell 500 shares of Ligand Pharmaceuticals Inc. common stock.
Key Highlights
- Seller: John W. Kozarich, identified in the filing as a Director of Ligand Pharmaceuticals Inc.
- Shares proposed for sale: 500 shares of common stock, with an aggregate market value of $158,659.25 according to the filing.
- Broker: UBS Financial Services, Inc., Eleven Madison Avenue, 4th Floor, New York, NY 10010, named as the executing broker.
- Approximate date of sale: November 11, 2026, on Nasdaq, as stated in the filing.
- Source of shares: Two stock awards from the issuer, 250 shares acquired on May 25, 2018, and 250 shares acquired on June 6, 2025.
- Rule 10b5-1 plan: The filing indicates a plan adoption date of August 12, 2026.
- Shares outstanding: The filing reports 20,002,986 shares of common stock outstanding.
Kozarich Proposes Sale of 500 Ligand Pharmaceuticals Shares Under 10b5-1 Plan
According to the Form 144 filing submitted to the SEC on November 12, 2026, John W. Kozarich, a director of Ligand Pharmaceuticals Inc. (NASDAQ:LGND), proposed to sell 500 shares of the company's common stock. The filing lists an aggregate market value of $158,659.25 for the proposed sale, with an approximate sale date of November 11, 2026, to be executed on Nasdaq through UBS Financial Services, Inc.
The filing discloses that the 500 shares subject to the proposed sale were acquired in two separate stock award transactions, both from the issuer. The first lot of 250 shares was awarded on May 25, 2018, and the second lot of 250 shares was awarded on June 6, 2025. The filing reports no securities sold by Kozarich during the past three months prior to this notice.
The notice states that the sale is being conducted in reliance on a written trading plan adopted on August 12, 2026, consistent with Rule 10b5-1 under the Exchange Act. UBS Financial Services, Inc. signed the form as attorney-in-fact for John Kozarich. The filing identifies Ligand Pharmaceuticals Inc. as having 20,002,986 shares of common stock outstanding at the time of the notice.
What Was Disclosed
Ligand Pharmaceuticals director John W. Kozarich filed a Form 144 on November 12, 2026, proposing to sell 500 shares of common stock with an aggregate market value of $158,659.25, acquired via stock awards in 2018 and 2025, under a Rule 10b5-1 plan adopted August 12, 2026.




Please wait processing your request...